Cyclic Glycine-Proline vs Dianabol
Moderate Research vs Well Studied
monitor Mechanism-based · 47% Both Cyclic Glycine-Proline and Dianabol affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Cyclic Glycine-Proline Dianabol
Weight 154.17 Da 300.44 Da
Half-life Extended stability (more stable than linear GPE precursor) ~4-6 hours
Chain 2 amino acids (cyclic) —
Type Cyclic dipeptide (2,5-diketopiperazine) 17-alpha-alkylated anabolic steroid (C20H28O2)
Key Benefits
Cyclic Glycine-Proline
01 Neuroprotection and cognitive enhancement
02 IGF-1 optimization
03 Cardiovascular support
04 Metabolic health improvement
05 Blood-brain barrier penetration
06 Convenient oral administration
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
Side Effects
Cyclic Glycine-Proline
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
Contraindications
Consult healthcare provider if taking IGF-1 or growth hormone medications
Limited long-term human data available
Not studied in pregnancy
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Research Evidence
Cyclic Glycine-Proline Dianabol
Status Moderate Research Well Studied
References 4 studies 5 studies
Latest — 2017
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.